| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.JAAD.2008.02.039 |
| P698 | PubMed publication ID | 18423260 |
| P50 | author | Craig A. Elmets | Q110142695 |
| P2093 | author name string | John Y M Koo | |
| Mark Lebwohl | |||
| Steven R Feldman | |||
| Alan Menter | |||
| Abby S Van Voorhees | |||
| Karl R Beutner | |||
| Reva Bhushan | |||
| Neil J Korman | |||
| Alice Gottlieb | |||
| Craig L Leonardi | |||
| Kenneth B Gordon | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | psoriatic arthritis | Q511097 |
| P304 | page(s) | 826-850 | |
| P577 | publication date | 2008-05-01 | |
| P1433 | published in | Journal of the American Academy of Dermatology | Q15757046 |
| P1476 | title | Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics | |
| P478 | volume | 58 |
| Q52844749 | "Drug-Survival"-Raten und Gründe für den Abbruch von Systemtherapien bei Psoriasis. |
| Q99567221 | 'Psoriasis 1' reduces T‑lymphocyte‑mediated inflammation in patients with psoriasis by inhibiting vitamin D receptor‑mediated STAT4 inactivation |
| Q48271832 | 9-cis-rich β-carotene powder of the alga Dunaliella reduces the severity of chronic plaque psoriasis: a randomized, double-blind, placebo-controlled clinical trial |
| Q34117369 | A Practical Approach to Home UVB Phototherapy for the Treatment of Generalized Psoriasis |
| Q48050791 | A clinical review of phototherapy for psoriasis. |
| Q42969984 | A comprehensive analysis of pattern recognition receptors in normal and inflamed human epidermis: upregulation of dectin-1 in psoriasis. |
| Q27334725 | A multicenter, non-interventional study to evaluate patient-reported experiences of living with psoriasis |
| Q36085078 | A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in pa |
| Q47657450 | A new class of biologic agents facing the therapeutic paradigm in psoriasis: anti-IL-23 agents. |
| Q38675867 | A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast |
| Q48257860 | A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents. |
| Q51103736 | A novel electromechanical autoinjector, AutoTouch™, for self-injection of etanercept: real-world use and benefits. |
| Q37898704 | A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency. |
| Q34156420 | A practical approach to monitoring patients on biological agents for the treatment of psoriasis |
| Q83117029 | A practical approach to screening psoriasis patients for therapy with biologic agents |
| Q37307635 | A statistical analysis plan for the efficiency and safety of Chinese herbal medicine used concurrently with topical therapy for psoriasis vulgaris |
| Q46506676 | A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis |
| Q38623340 | A systematic review on the efficacy and safety of Infliximab in patients with psoriasis |
| Q60683249 | Abordaje integral de la comorbilidad del paciente con psoriasis |
| Q26830499 | Activated protein C: A regulator of human skin epidermal keratinocyte function |
| Q36521206 | Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials. |
| Q37142425 | Adalimumab in dermatology |
| Q34975485 | Add-on effect of chinese herbal medicine bath to phototherapy for psoriasis vulgaris: a systematic review |
| Q37628279 | Adherence to guidelines in the use of biological agents to treat psoriasis in Brazil |
| Q37427086 | Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature |
| Q37868389 | Advances in the treatment of moderate-to-severe plaque psoriasis |
| Q38569794 | An overview of developing TNF-α targeted therapy for the treatment of psoriasis |
| Q34944668 | Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece |
| Q52844436 | Anti-TNF associated psoriasis. |
| Q37517101 | Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence |
| Q38760881 | Anti-interleukin-17 treatment of psoriasis |
| Q54966155 | Antipsoriatic Effects of Wannachawee Recipe on Imiquimod-Induced Psoriasis-Like Dermatitis in BALB/c Mice. |
| Q37998917 | Application of the dermatology life quality index in clinical trials of biologics for psoriasis |
| Q34476049 | Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists |
| Q35896444 | Apremilast (Otezla): A New Oral Treatment for Adults With Psoriasis and Psoriatic Arthritis. |
| Q38019980 | Apremilast as a treatment for psoriasis |
| Q39170240 | Apremilast for the management of moderate to severe plaque psoriasis |
| Q38202205 | Apremilast for the treatment of psoriatic arthritis |
| Q37505449 | Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: A novel treatment option for nurse practitioners treating patients with psoriatic disease |
| Q36968787 | Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3) |
| Q38702419 | Apremilast: A Novel Drug for Treatment of Psoriasis and Psoriatic Arthritis |
| Q36942993 | Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis |
| Q39141679 | Apremilast: A Review in Psoriasis and Psoriatic Arthritis |
| Q38209439 | Apremilast: first global approval |
| Q55109332 | Assessing the effectiveness of synthetic and biologic disease-modifying antirheumatic drugs in psoriatic arthritis - a systematic review. |
| Q92616693 | Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response |
| Q55153984 | Assessment and monitoring of biologic drug adverse events in patients with psoriasis. |
| Q36607070 | Assessment of the Therapeutic Aspect of Systemic Non-Biologic Anti-Psoriatic Treatment Modalities Used in Combination with Methotrexate |
| Q57488548 | Association of ERAP1 gene polymorphisms with the susceptibility to psoriasis vulgaris: A case-control study |
| Q93030527 | Association of Psoriasis With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis |
| Q39165773 | Association of chronic periodontitis and psoriasis: periodontal status with severity of psoriasis |
| Q64891361 | Auricular acupressure as a complementary therapy for psoriasis vulgaris: study protocol for a multicenter randomized controlled trial. |
| Q38123192 | Biologic fatigue in psoriasis. |
| Q30412650 | Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring |
| Q37095210 | Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population. |
| Q38229869 | Biologic therapy with or without topical treatment in psoriasis: what does the current evidence say? |
| Q38155648 | Biological therapies for psoriasis |
| Q37993932 | Biologics in oral medicine: principles of use and practical considerations |
| Q34620257 | Biologics in the management of psoriasis. |
| Q37607414 | Biologics in the treatment of psoriasis: clinical and economic overview |
| Q38781048 | Biologics use in Indian psoriasis patients |
| Q35592362 | Bone-immune cell crosstalk: bone diseases. |
| Q38743710 | Budget impact model in moderate-to-severe psoriasis vulgaris assessing effects of calcipotriene and betamethasone dipropionate foam on per-patient standard of care costs |
| Q26747639 | Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective |
| Q38114850 | Burden of disease: psoriasis and psoriatic arthritis |
| Q38811080 | Calcipotriene and betamethasone dipropionate for the topical treatment of plaque psoriasis |
| Q38704121 | Calcipotriene betamethasone dipropionate aerosol foam in the treatment of plaque psoriasis: a review of the literature |
| Q33650112 | Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study |
| Q53034596 | Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. |
| Q93347788 | Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison |
| Q38963067 | Calcipotriol/Betamethasone Dipropionate Foam: A Review in Plaque Psoriasis |
| Q57816525 | Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: case series and review of the literature |
| Q36742161 | Candidate gene polymorphisms and risk of psoriasis: A pilot study. |
| Q43542364 | Case of coexisting psoriatic arthritis and bullous pemphigoid improved by etanercept |
| Q38630723 | Characterizing patients with psoriasis on injectable biologics adalimumab, etanercept, and ustekinumab: A chart review study |
| Q34469802 | Chinese medicine combined with calcipotriol betamethasone and calcipotriol ointment for Psoriasis vulgaris (CMCBCOP): study protocol for a randomized controlled trial |
| Q46247849 | Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say? |
| Q39719679 | Chronic administration of cyclosporine A changes expression of BDNF and TrkB in rat hippocampus and midbrain |
| Q90217061 | Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis |
| Q38058361 | Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. |
| Q50517177 | Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis. |
| Q38339763 | Combination therapy of cyclosporine and anti-tumor necrosis factor α in psoriasis: a case series of 10 patients |
| Q52564825 | Common Contact Allergens in Patients with Palmoplantar and Scalp Psoriasis and Impact of their Avoidance on Dermatology Life Quality Index: A Hospital-Based Study. |
| Q48072913 | Comorbidities and health-related quality of life in Spanish patients with moderate to severe psoriasis: a cross-sectional study (Arizona study). |
| Q34502118 | Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab |
| Q36334747 | Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. |
| Q46463583 | Comparison of gene expression profiles reveals aberrant expression of FOXO1, Aurora A/B and EZH2 in lesional psoriatic skins |
| Q48297086 | Comparison of psoriasis and atopic dermatitis guidelines-an argument for aggressive atopic dermatitis management. |
| Q38474670 | Comparisons of gene expression in normal, lesional, and non-lesional psoriatic skin using DNA microarray techniques |
| Q83951416 | Complete resolution of guttate psoriasis following autologous SCT for Ewing's sarcoma in a pediatric patient |
| Q38376367 | Compound glycyrrhizin plus conventional therapy for psoriasis vulgaris: a systematic review and meta-analysis of randomized controlled trials |
| Q92465025 | Considerable variation among Iranian dermatologists in the knowledge and attitudes regarding the use of biologic agents to manage psoriasis |
| Q47294822 | Contribution of In Vivo and Organotypic 3D Models to Understanding the Role of Macrophages and Neutrophils in the Pathogenesis of Psoriasis |
| Q59809931 | Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain |
| Q46945261 | Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States |
| Q88495316 | Cost-Effectiveness of Biologic Agents in the Treatment of Moderate-to-Severe Psoriasis: A Brazilian Public Health Service Perspective |
| Q53172684 | Critical appraisal of quality of clinical practice guidelines for treatment of psoriasis vulgaris, 2006-2009. |
| Q38039491 | Current and emerging systemic treatment strategies for psoriasis |
| Q38205138 | Current concepts in psychodermatology |
| Q37991748 | Current investigational drugs in psoriasis |
| Q55044800 | Current knowledge on psoriasis and autoimmune diseases. |
| Q36057909 | Current status and future prospects for biologic treatments of psoriasis |
| Q34112840 | Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents |
| Q41011793 | Custom-made micro applicators for high-dose-rate brachytherapy treatment of chronic psoriasis. |
| Q37630268 | Cytokine Imbalance as a Common Mechanism in Both Psoriasis and Rheumatoid Arthritis. |
| Q47147173 | DFD-01 Reduces Transepidermal Water Loss and Improves Skin Hydration and Flexibility |
| Q34516612 | Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR) |
| Q37977994 | Demyelination during tumour necrosis factor antagonist therapy for psoriasis: a case report and review of the literature. |
| Q39417482 | Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression |
| Q47116889 | Dermatologist and Patient Preferences in Choosing Treatments for Moderate to Severe Psoriasis |
| Q35571621 | Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients |
| Q43461744 | Development of MGUS in psoriatic patients: a possible undiagnosed event during anti-TNF-α-treatment. |
| Q38165235 | Diagnosing and treating psoriatic arthritis: an update |
| Q33558495 | Diagnosis and management of psoriasis |
| Q92088338 | Diagnostic role of ultrasound elastography for nail bed involvement in psoriasis |
| Q58764407 | Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis moderada a grave con agentes biológicos |
| Q37998915 | Disease-syndrome combination clinical study of psoriasis: present status, advantages, and prospects |
| Q48126622 | Dissatisfaction with cutaneous body image is directly correlated with insomnia severity: A prospective study in a non-clinical sample |
| Q46118586 | Drug survival of biologic treatments in psoriasis: a systematic review. |
| Q47624590 | Drug survival rates and reasons for drug discontinuation in psoriasis |
| Q37268868 | Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis |
| Q38064467 | Effect of Biologic Agents on Non-PASI Outcomes in Moderate-to-Severe Plaque Psoriasis: Systematic Review and Meta-Analyses |
| Q64088737 | Effect of Korean medicine as add-on therapy to phototherapy for psoriasis: Two case reports |
| Q38285771 | Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review. |
| Q35637208 | Effect of etanercept therapy on psoriasis symptoms in patients from Latin America, Central Europe, and Asia: a subset analysis of the PRISTINE trial |
| Q38446877 | Effect of lifestyle weight loss intervention on disease severity in patients with psoriasis: a systematic review and meta-analysis |
| Q42870686 | Effective Strategies for the Management of Pyoderma Gangrenosum |
| Q47169165 | Effects of Wannachawee Recipe with Antipsoriatic Activity on Suppressing Inflammatory Cytokine Production in HaCaT Human Keratinocytes |
| Q33713076 | Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials. |
| Q44554932 | Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study |
| Q37693862 | Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam Compared with Betamethasone 17-Valerate-Medicated Plaster for the Treatment of Psoriasis |
| Q36811632 | Efficacy and safety of Tripterygium wilfordii hook F versus acitretin in moderate to severe psoriasis vulgaris: a randomized clinical trial |
| Q46735206 | Efficacy and safety of adalimumab in psoriatic patients previously treated with etanercept in a real-world setting. |
| Q38198080 | Efficacy and safety of etanercept in chronic immune-mediated disease |
| Q35643453 | Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials |
| Q47349992 | Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials |
| Q36190962 | Efficacy of Immunobiologic and Small Molecule Inhibitor Drugs for Psoriasis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials |
| Q34497018 | Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH |
| Q35203542 | Efficacy of an innovative aerosol foam formulation of fixed combination calcipotriol plus betamethasone dipropionate in patients with psoriasis vulgaris |
| Q36094590 | Efficacy of combining oral Chinese herbal medicine and NB-UVB in treating psoriasis vulgaris: a systematic review and meta-analysis |
| Q90465560 | Efficacy of several biological therapies for treating moderate to severe psoriasis: A network meta-analysis |
| Q48268355 | Efficiency and safety of a Curcuma extract combined with visible blue light phototherapy on adults with plaque psoriasis: A phase IV, randomized, open pilot clinical trial. |
| Q38166017 | Emerging topical treatments for psoriasis |
| Q46806771 | Epidemiology of moderate-to-severe plaque psoriasis in a Canadian surveyed population. |
| Q37467570 | Erythrodermic Psoriasis Treated with Apremilast |
| Q86900636 | Essential Role of microRNA in Skin Physiology and Disease |
| Q34620263 | Etanercept in the treatment of plaque psoriasis |
| Q38027577 | Etanercept provides an effective, safe and flexible short- and long-term treatment regimen for moderate-to-severe psoriasis: a systematic review of current evidence |
| Q45364783 | Etanercept therapy in a hepatitis B virus (HBV)-positive psoriatic patient developing a monoclonal gammopathy of undetermined significance. |
| Q39180810 | Etanercept, improved dosage schedules and combinations in the treatment of psoriasis: an update |
| Q38230740 | Etanercept: a review of its use in autoimmune inflammatory diseases |
| Q37954714 | Etanercept: efficacy and safety for approved indications |
| Q33729774 | Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight |
| Q36091617 | Evaluating practice patterns for managing moderate to severe plaque psoriasis: role of the family physician |
| Q37682855 | Evaluation of psoriasis patients' attitudes toward benefit-risk and therapeutic trade-offs in their choice of treatments |
| Q38838470 | Experience and challenges for biologic use in the treatment of moderate-to-severe psoriasis in Africa and the Middle East region. |
| Q92375847 | Exploration of the Product of the 5-Point Investigator's Global Assessment and Body Surface Area (IGA × BSA) as a Practical Minimal Disease Activity Goal in Patients with Moderate-to-Severe Psoriasis |
| Q52614673 | First-in-man intravenous implantation of stromal vascular fraction in psoriasis: a case study. |
| Q39034449 | Fixed combination calcipotriol plus betamethasone dipropionate aerosol foam in the treatment of psoriasis vulgaris: rationale for development and clinical profile. |
| Q37901473 | Focus on skin cancer association and progression under TNF antagonist therapy |
| Q61805638 | Fractional laser ablation for the targeted cutaneous delivery of an anti-CD29 monoclonal antibody - OS2966 |
| Q35215230 | G-231A and G+70C Polymorphisms of Endothelin Receptor Type-A Gene could Affect the Psoriasis Area and Severity Index Score and Endothelin 1 Levels |
| Q39205065 | Genetic markers of treatment response to tumour necrosis factor-α inhibitors in the treatment of psoriasis. |
| Q37953810 | Genetics of susceptibility and treatment response in psoriatic arthritis |
| Q34626982 | Glutathione peroxidase activity in the blood cells of psoriatic patients correlates with their responsiveness to Efalizumab |
| Q38716028 | Healthcare costs in psoriasis and psoriasis sub-groups over time following psoriasis diagnosis |
| Q51362052 | Healthcare resource utilization, healthcare costs and dose escalation in psoriasis patients initiated on ustekinumab versus adalimumab: a retrospective claim study. |
| Q39371287 | Heterogeneity of response to biologic treatment: perspective for psoriasis |
| Q36872980 | Hidradenitis Suppurativa Management in the United States: An Analysis of the National Ambulatory Medical Care Survey and MarketScan Medicaid Databases |
| Q36921945 | How psoriasis patients perceive, obtain, and use biologic agents: Survey from an academic medical center. |
| Q42210089 | Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO. |
| Q64100041 | Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry |
| Q38632525 | Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab |
| Q36843650 | Improving cardiovascular health and metabolic comorbidities in patients with psoriatic arthritis |
| Q46337002 | Incidence and Prevalence of Cardiovascular Risk Factors Among Patients With Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis |
| Q42240106 | Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005-09. |
| Q37500781 | Increased IL17A, IFNG, and FOXP3 Transcripts in Moderate-Severe Psoriasis: A Major Influence Exerted by IL17A in Disease Severity. |
| Q38614179 | Increased risk of herpes zoster in patients with psoriasis: A population-based retrospective cohort study. |
| Q38335718 | Infection risk associated with anti-TNF-α agents: a review |
| Q92626116 | Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events |
| Q38132707 | Infliximab in psoriasis and psoriatic arthritis. |
| Q88501801 | Inhibition of interleukin-12 and/or interleukin-23 for the treatment of psoriasis: What is the evidence for an effect on malignancy? |
| Q38902108 | Initiation, Switching, and Cessation of Psoriasis Treatments Among Patients with Moderate to Severe Psoriasis in the United States |
| Q93508292 | Introduction |
| Q92605866 | Investigation of psoriasis skin tissue by label-free multi-modal imaging: a case study on a phototherapy-treated patient |
| Q92481916 | Is There Any Association Between Psoriasis and Hashimoto's Thyroiditis? |
| Q34074149 | Is There a Potential Role for Anti-tumor Necrosis Factor Therapy in Patients with Human Immunodeficiency Virus? |
| Q47898256 | Is psoriasis an autoimmune disease? Interpretations from an immunofluorescence-based study. |
| Q37400338 | Is there truly a risk of lymphoma from biologic therapies? |
| Q50891846 | Isoniazid therapy for latent tuberculosis in psoriasis patients receiving biological agents: is it safe and efficacious? |
| Q47245442 | Itching for answers: Prevalence and severity of pruritus in psoriasis |
| Q38137283 | Japanese guidance for use of biologics for psoriasis (the 2013 version). |
| Q38110734 | Keratin 17: a critical player in the pathogenesis of psoriasis |
| Q37468351 | Long-Term Cost-Effectiveness Analysis of Etanercept and Adalimumab for Plaque Psoriasis not Associated with Arthritis |
| Q51435941 | Long-term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate-to-severe plaque psoriasis. |
| Q34620323 | Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature |
| Q37961072 | Management of psoriasis in Africa and the Middle East: a review of current opinion, practice and opportunities for improvement |
| Q28078157 | Management of psoriasis patients with hepatitis B or hepatitis C virus infection |
| Q37930978 | Management of psoriatic arthritis from the view of the dermatologist |
| Q54941753 | Management of scalp psoriasis: current perspectives. |
| Q40114903 | Managing Mild-to-Moderate Psoriasis in Elderly Patients: Role of Topical Treatments. |
| Q26771785 | Managing Patients With Psoriasis in the Busy Clinic: Practical Tips for Health Care Practitioners |
| Q27693878 | Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis |
| Q64970264 | Mesenchymal Stem Cell Conditioned Media Ameliorate Psoriasis Vulgaris: A Case Study. |
| Q40090542 | Meta-analysis of the Efficacy and Safety of Secukinumab for the Treatment of Plaque Psoriasis |
| Q47097957 | MicroRNA-520a suppresses the proliferation and mitosis of HaCaT cells by inactivating protein kinase B. |
| Q38726898 | MicroRNA138 regulates keratin 17 protein expression to affect HaCaT cell proliferation and apoptosis by targeting hTERT in psoriasis vulgaris |
| Q48254045 | Might psoriasis be a risk factor for obstructive sleep apnea syndrome? |
| Q42293363 | Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study |
| Q45977850 | Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis. |
| Q41967507 | More Biologic Therapies Expected To Treat Advanced Plaque Psoriasis |
| Q88991292 | Multiple Skin Cancers Following Psoralen and Ultraviolet A Treatment of Psoriasis |
| Q39004668 | Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications |
| Q26800937 | New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors |
| Q27001941 | New era of biologic therapeutics in atopic dermatitis |
| Q37381676 | New insights into the pathogenesis and genetics of psoriatic arthritis |
| Q34088571 | No increased risk of cancer after coal tar treatment in patients with psoriasis or eczema. |
| Q38211315 | Novel methods of measuring clinical outcomes from psoriasis and psoriatic arthritis clinical trials |
| Q38628193 | Novel systemic therapies for the treatment of psoriasis |
| Q26859617 | Nuclear hormone receptor functions in keratinocyte and melanocyte homeostasis, epidermal carcinogenesis and melanomagenesis |
| Q48023865 | Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in Japan |
| Q35246473 | Oral Chinese herbal medicine combined with pharmacotherapy for psoriasis vulgaris: a systematic review. |
| Q36691601 | Oral PSORI-CM01, a Chinese herbal formula, plus topical sequential therapy for moderate-to-severe psoriasis vulgaris: pilot study for a double-blind, randomized, placebo-controlled trial |
| Q54214722 | Oral Tofacitinib for the Treatment of Adults with Moderate to Severe Chronic Plaque Psoriasis. |
| Q34996214 | Oral granulated Chinese herbal medicine (YXBCM01) plus topical calcipotriol for psoriasis vulgaris: study protocol for a double-blind, randomized placebo controlled trial. |
| Q50068335 | PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis |
| Q43433302 | Paradoxical worsening of psoriasis when switching from etanercept to adalimumab: a case series |
| Q48144635 | Pathogenesis of psoriasis and development of treatment |
| Q35658540 | Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment |
| Q33800651 | Patient considerations and targeted therapies in the management of psoriasis in Chinese patients: role of ustekinumab |
| Q37735799 | Patient experience with intravenous biologic therapies for ankylosing spondylitis, Crohn's disease, psoriatic arthritis, psoriasis, rheumatoid arthritis, and ulcerative colitis |
| Q44849386 | Patient preferences for psoriasis treatments: impact of treatment experience |
| Q47877368 | Patient-relevant treatment goals in psoriasis |
| Q45977006 | Patients' Perspectives on the Impact of Genital Psoriasis: A Qualitative Study. |
| Q39165009 | Patients' perspectives in the management of psoriasis: the Italian results of the Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey. |
| Q44773623 | Pattern of response in patients with moderate-to-severe psoriasis treated with etanercept |
| Q57445009 | Pediatric psoriasis |
| Q37776736 | Perioperative management of tumor necrosis factor antagonists in patients with psoriasis and other inflammatory disorders |
| Q36691823 | Periostin contributes to epidermal hyperplasia in psoriasis common to atopic dermatitis |
| Q64288920 | Peroxisome proliferator-activated receptor-γ gene polymorphism in psoriasis and its relation to obesity, metabolic syndrome, and narrowband ultraviolet B response: A case–control study in Egyptian patients |
| Q38885459 | Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis. |
| Q38690745 | Pharmacogenetic markers to predict the clinical response to methotrexate in south Indian Tamil patients with psoriasis |
| Q38856372 | Pharmacogenetics and pharmacogenomics in psoriasis treatment: current challenges and future prospects |
| Q37822759 | Pharmacogenetics of psoriasis |
| Q36600202 | Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature |
| Q38169210 | Phototherapy, psoriasis, and the age of biologics |
| Q37268881 | Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey |
| Q47974732 | Pictorial representation of illness and self measure (PRISM): an effective tool to assess the burden of psoriasis |
| Q38086585 | Pimecrolimus for psoriasis. |
| Q38815834 | Pituitary tumor transforming gene PTTG2 induces psoriasis by regulating vimentin and E-cadherin expression |
| Q39144447 | Ponesimod--a future oral therapy for psoriasis? |
| Q51092732 | Population exposure-response model to support dosing evaluation of ixekizumab in patients with chronic plaque psoriasis. |
| Q37607426 | Practical aspects of prescribing a biologic |
| Q82610565 | Pregnancy outcomes in women with moderate‐to‐severe psoriasis |
| Q64079052 | Preparation of sustained release apremilast-loaded PLGA nanoparticles: in vitro characterization and in vivo pharmacokinetic study in rats |
| Q39106788 | Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink |
| Q38720306 | Prioritizing disease-causing microbes based on random walking on the heterogeneous network |
| Q58694359 | Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date |
| Q36628064 | Providing Guidance for Patients With Moderate-to-Severe Psoriasis Who Are Candidates for Biologic Therapy: Role of the Nurse Practitioner and Physician Assistant |
| Q88836318 | Psoriasis |
| Q36185077 | Psoriasis and cardiovascular risk: strength in numbers, part II. |
| Q30235888 | Psoriasis and comorbid diseases: Implications for management |
| Q36824796 | Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies |
| Q39967628 | Psoriasis and the liver: problems, causes and course |
| Q38420877 | Psoriasis during pregnancy: characteristics and important management recommendations |
| Q35996755 | Psoriasis in the US Medicare Population: Prevalence, Treatment, and Factors Associated with Biologic Use |
| Q84607554 | Psoriasis market |
| Q41255645 | Psoriasis patients' willingness to accept side-effect risks for improved treatment efficacy. |
| Q45777991 | Psoriasis prevalence among the 2009 AAD National Melanoma/Skin Cancer Screening Program participants. |
| Q33809992 | Psoriasis, Psoriatic Arthritis, and Thyroid Autoimmunity |
| Q33939033 | Psoriasis, anti-tumor necrosis factor therapy, and tuberculosis: report of three challenging cases and literature review |
| Q26744032 | Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same? |
| Q28088340 | Psoriasis: classical and emerging comorbidities |
| Q38018691 | Psoriasis: new insight about pathogenesis, role of barrier organ integrity, NLR / CATERPILLER family genes and microbial flora. |
| Q37793830 | Psoriasis: what we have learned from mouse models |
| Q40017163 | Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis |
| Q52332581 | Quality of Care in Rheumatoid Disease from the Clinician Perspective: A Modified Delphi Panel Approach. |
| Q42555631 | Quantitative and simultaneous non-invasive measurement of skin hydration and sebum levels |
| Q93258073 | ROLE OF PHOTOTHERAPY IN THE ERA OF BIOLOGICS |
| Q38907492 | Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3. |
| Q38630637 | Rate of serious infection in patients who are prescribed systemic biologic or nonbiologic agents for psoriasis: A large, single center, retrospective, observational cohort study |
| Q42129151 | Rational Vehicle Design Ensures Targeted Cutaneous Steroid Delivery |
| Q30658185 | Rationale and early clinical data on IL-17 blockade in psoriasis |
| Q37309074 | Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52-week PRO-long study |
| Q33872389 | Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? |
| Q38202032 | Recent advances in paediatric dermatology |
| Q64245109 | Recommendations for Initiating Systemic Therapy in Patients with Psoriasis |
| Q39248590 | Reformulations of well-known active ingredients in the topical treatment of psoriasis vulgaris can improve clinical outcomes for patients |
| Q34910888 | Relation between psoriasis and geographic tongue |
| Q39563894 | Reliability and validity of the Psoriasis Itch Visual Analog Scale in psoriasis vulgaris |
| Q47143243 | Response to Tetanus and Pneumococcal Vaccination Following Administration of Ixekizumab in Healthy Participants |
| Q46131367 | Review of IL-17 inhibitors for psoriasis |
| Q38961129 | Safety and Efficacy of Brodalumab for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis |
| Q38166663 | Safety and tolerability of tumor necrosis factor-α inhibitors in psoriasis: a narrative review |
| Q37980484 | Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis |
| Q37892162 | Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review |
| Q30577671 | Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. |
| Q38411930 | Screening and vaccinations in patients requiring systemic immunosuppression: an update for dermatologists |
| Q38636359 | Secukinumab for treating plaque psoriasis |
| Q44874974 | Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial. |
| Q48358207 | Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis. |
| Q38636664 | Secukinumab is the most efficient treatment for achieving clear skin in psoriatic patients: a cost-consequence study from the Spanish National Health Service. |
| Q49985388 | Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis |
| Q53778903 | Serum level of receptor activator of nuclear factor kappa-B ligand in patients with psoriasis. |
| Q38078763 | Sirtuins in dermatology: applications for future research and therapeutics |
| Q34613907 | Spondyloarthritides: evolving therapies |
| Q30361133 | Subclinical enthesopathy in patients with psoriasis and its association with other disease parameters: a power Doppler ultrasonographic study |
| Q88812010 | Subsequent Cardiovascular Events Among Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis: Patterns of Disease-Modifying Antirheumatic Drug Treatment |
| Q51731250 | Successful Treatment of Inflammatory Linear Verrucous Epidermal Nevus with Concomitant Psoriasis Using Etanercept. |
| Q91842778 | Successful Treatment of Plaque Psoriasis with Allogeneic Gingival Mesenchymal Stem Cells: A Case Study |
| Q36635181 | Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris--A randomized phase II study |
| Q37150168 | Supersaturation of Calcipotriene and Betamethasone Dipropionate in a Novel Aerosol Foam Formulation for Topical Treatment of Psoriasis Provides Enhanced Bioavailability of the Active Ingredients |
| Q53241655 | Systematic bias in predictions of new drugs' budget impact: analysis of a sample of recent US drug launches. |
| Q92277529 | Systemic Psoriasis Therapies and Comorbid Disease in Patients with Psoriasis: A Review of Potential Risks and Benefits |
| Q61804182 | T cell-intrinsic prostaglandin E-EP2/EP4 signaling is critical in pathogenic T17 cell-driven inflammation |
| Q40543657 | TUR-PSO: A cross-sectional, study investigating quality of life and treatment status of psoriasis patients in Turkey |
| Q47140713 | Targeting IL-17 in psoriatic arthritis |
| Q40006527 | Tele-assessment of Psoriasis Area and Severity Index: a study of the accuracy of digital image capture. |
| Q37689670 | Th17 and Th22 cells in psoriatic arthritis and psoriasis |
| Q34393068 | The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. |
| Q39649534 | The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives. |
| Q33572834 | The Challenge of Managing Psoriasis: Unmet Medical Needs and Stakeholder Perspectives |
| Q64241342 | The Challenge of Variable Costs in Decisions Based on Cost-Effectiveness Evidence: A Case Study for Brodalumab |
| Q38566345 | The Relationship of Obesity With the Severity of Psoriasis: A Systematic Review |
| Q55555049 | The Role of Forkhead Box Class O3A and SIRT1 Gene Variants in Early-Onset Psoriasis. |
| Q42090633 | The Th17/IL-23 Axis and Natural Immunity in Psoriatic Arthritis |
| Q99566147 | The Unmet Need for Clinical Guidelines on the Management of Patients with Plaque Psoriasis in Africa and the Middle East |
| Q34785582 | The antipsoriatic agent monomethylfumarate has antiproliferative, prodifferentiative, and anti-inflammatory effects on keratinocytes. |
| Q35199755 | The association of psoriasis and elevated blood lipids in overweight and obese children. |
| Q34432846 | The burden of psoriatic arthritis: a literature review from a global health systems perspective. |
| Q43760972 | The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study |
| Q55056080 | The evaluation of the clinical effect of topical St Johns wort (Hypericum perforatum L.) in plaque type psoriasis vulgaris: a pilot study. |
| Q38952685 | The prevalence of anxiety in patients with psoriasis: a systematic review of observational studies and clinical trials |
| Q38707588 | The role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis. |
| Q34076431 | The role of TNF inhibitors in psoriasis therapy: new implications for associated comorbidities |
| Q38217029 | The role of interleukin-17A in psoriatic disease |
| Q38820563 | The role of specialty pharmacy drugs in the management of inflammatory diseases |
| Q46758133 | The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection |
| Q44509047 | The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. |
| Q92277795 | The seroconversion rate of QuantiFERON-TB Gold In-Tube test in psoriatic patients receiving secukinumab and ixekizumab, the anti-interleukin-17A monoclonal antibodies |
| Q92504960 | Therapeutic Effects of Synthetic Antimicrobial Peptides, TRAIL and NRP1 Blocking Peptides in Psoriatic Keratinocytes |
| Q58766145 | Therapeutic Efficacies of Extract Cream Formulation in Imiquimod-Induced Psoriasis Models |
| Q64054927 | Therapeutic Implication of SOCS1 Modulation in the Treatment of Autoimmunity and Cancer |
| Q38098466 | Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents |
| Q48322904 | Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis |
| Q38856883 | Tofacitinib for the treatment of psoriasis |
| Q37693752 | Topical medication utilization and health resources consumption in adult patients affected by psoriasis: findings from the analysis of administrative databases of local health units |
| Q37766897 | Topical treatment of psoriasis |
| Q47602117 | Treating Moderate-to-Severe Plaque Psoriasis With Guselkumab: A Review of Phase II and Phase III Trials |
| Q46026172 | Treating psoriasis with etanercept in italian clinical practice: prescribing practices and duration of remission following discontinuation. |
| Q38014313 | Treatment algorithms for early psoriatic arthritis: do they depend on disease phenotype? |
| Q38132706 | Treatment of psoriasis and psoriatic arthritis |
| Q38207916 | Treatment of psoriasis: focus on clinic-based management with infliximab |
| Q39239428 | Treatment patterns in moderate-to-severe plaque psoriasis: results from a Belgian cross-sectional study (DISCOVER). |
| Q34267352 | Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs |
| Q38034134 | Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings |
| Q38210615 | Treatment patterns with topicals, traditional systemics and biologics in psoriasis - a Swedish database analysis. |
| Q93061961 | Treatment patterns, unmet need, and impact on patient-reported outcomes of psoriatic arthritis in the United States and Europe |
| Q42646805 | Treatment preferences for biologicals in psoriasis: experienced patients appreciate sustainability |
| Q37660470 | Treatment sequencing after failure of the first biologic in cost-effectiveness models of psoriasis: a systematic review of published models and clinical practice guidelines. |
| Q26829390 | Tumor necrosis factor-α inhibitors and chronic hepatitis C: a comprehensive literature review |
| Q36521222 | US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey |
| Q35922839 | Ultraviolet B Phototherapy for Psoriasis: Review of Practical Guidelines |
| Q34449302 | Ultraviolet Phototherapy Management of Moderate-to-Severe Plaque Psoriasis: An Evidence-Based Analysis. |
| Q31146263 | Under-Treatment of Patients with Moderate to Severe Psoriasis in the United States: Analysis of Medication Usage with Health Plan Data |
| Q34620375 | Update of the management of chronic psoriasis: new approaches and emerging treatment options. |
| Q38884166 | Urinary Biopyrrins: A New Marker of Oxidative Stress in Psoriasis |
| Q35915882 | Use of Kv1.3 blockers for inflammatory skin conditions. |
| Q45361805 | Use of anti-tumor necrosis factor-α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan |
| Q34553755 | Use of biologic agents in combination with other therapies for the treatment of psoriasis |
| Q48160760 | Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey |
| Q41030609 | Use of tumor necrosis factor alpha (TNF α) antagonists in a patient with psoriasis and Chagas disease |
| Q24651927 | Ustekinumab |
| Q58008027 | Ustekinumab (Stelara®1)2 |
| Q81295694 | Ustekinumab for chronic plaque psoriasis |
| Q24596756 | Ustekinumab in psoriasis immunopathology with emphasis on the Th17-IL23 axis: a primer |
| Q37523846 | Ustekinumab: a new option in psoriasis therapy |
| Q37929165 | Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis |
| Q34041797 | Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis |
| Q35096980 | Ustekinumab: differential use in psoriasis |
| Q37578128 | Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis. |
| Q34340028 | Value of entheseal ultrasonography and serum cartilage oligomeric matrix protein in the preclinical diagnosis of psoriatic arthritis |
| Q42662607 | Work productivity and healthcare resource utilization outcomes for patients on etanercept for moderate-to-severe plaque psoriasis: results from a 1-year, multicentre, open-label, single-arm study in a clinical setting. |
| Q36175745 | Worldwide utilization of topical remedies in treatment of psoriasis: a systematic review. |
| Q84279851 | [Combined therapy with etanercept and systemic drugs or phototherapy] |
| Q84279838 | [Short term efficacy and safety of etanercept in psoriasis] |
| Q38721463 | microRNA-130a Promotes Human Keratinocyte Viability and Migration and Inhibits Apoptosis Through Direct Regulation of STK40-Mediated NF-κB Pathway and Indirect Regulation of SOX9-Meditated JNK/MAPK Pathway: A Potential Role in Psoriasis |
| Q33558550 | Diagnostic et prise en charge du psoriasis |
Search more.